UPENDS
UPENDS, an e-cigarette brand that prioritizes users’ experience and aims to become the favorite brand for vapers, has recently released its brand new next-gen mesh coil technology and UpBAR GT, the world’s first car concept disposable vape equipped with the next-gen mesh coil.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221227005002/en/
(Photo: Business Wire)
What Does the Next-gen Mesh Coil Mean to the Vape Market?
With the surge of the disposable vape market, countless manufacturers and brands influx into this track, pushing technology innovation quickly. Mesh coil, the key tech of disposable vapes, becomes the essential of tech innovation, which profoundly influences performance like flavor reproduction and puffs. It is obvious that products with stronger next-gen mesh coils will be more competitive in the market.
Next-gen Mesh Coil Comes with Significant Improvements in Performance.
Since the release of its “Mesh Coil is the Future” brand proposition, UPENDS has been dedicated to the innovation of mesh coil technology and has made many breakthroughs. After lab tests and adjustments, UPENDS next-gen mesh coil has been invented successfully. “Compared with traditional mesh coils, its flavor reproduction increased by 38%, puffs increased by 33% and energy efficiency increased by 36% with the same e-liquid capacity”, said Doctor WU, the Chief Product Officer of UPENDS. “We are so excited to release the next-gen mesh coil, and we believe that our customers will be satisfied with the strong performance and longevity it brings.”
UPENDS Makes A Comprehensive Breakthrough in Mesh Coil Technology.
Not only optimizing the coil, UPENDS has also upgraded technologies of the whole cotton coil platform for better performance and quality control. It features a V-shaped air inlet design that can accelerate aerosol delivery, decrease condensate and provide stronger smoke, compared with normal straight channels. Meanwhile, there’s literally no possibility of burnt tastes and oil leakage thanks to its industry-first Tesla value, unique separate air exchange and e-liquid supply channels and multi-layer seal leakage-proof. In addition, it adopts fully-automated manufacturing process technology, aiming to guarantee both production efficiency and stable high quality.
UpBAR GT with Next-gen Mesh Coil is Coming in January 2023.
So what does the next-gen mesh coil bring to UPENDS? UpBAR GT, the first disposable vape equipped with this technology will be the answer. As the “World’s First Car Concept Disposable Vape”, UpBAR GT seeks inspiration from sports cars and stands out from the crowd with its streamlined design and V-shaped grille decorations. GT is the abbreviation of Grand Touring, a type of car designed for high speed and long-distance driving, which also implies the features such as high quality, stability, security and more of UpBAR GT. In addition, there is an eco-friendly version using recycled materials.
About UPENDS
Founded in 2019, UPENDS is an e-cigarette brand dedicated to the field of Electronic Nicotine Delivery Systems. The good reputation of UPENDS as a leading e-cigarette brand in Europe attributes to its excellent manufacturing technology and quality, simple design, and cost-effective features. Currently, UPENDS is expanding its global development. UPENDS persistent pursuit is to prioritize users’ experience and to be Vaper's favorite. For more information, please visit www.upends.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005002/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom